Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities

Blood

Volumn 127, Issue 14, 2016, Pages 1814-1822

  Bernaudin, Françoise ^a,b   Verlhac, Suzanne ^a   Arnaud, Cécile ^a,b   Kamdem, Annie ^a,b   Hau, Isabelle ^b   Leveillé, Emmanuella ^a,b   Vasile, Manuela ^a   Kasbi, Florence ^a   Madhi, Fouad ^b   Fourmaux, Christine ^b   Biscardi, Sandra ^b   Gluckman, Eliane ^c   Socié, Gérard ^c   Dalle, Jean Hugues ^d   Epaud, Ralph ^b,e   Pondarré, Corinne ^a,b,e  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b Department of Pediatrics ^*  (France)

^c Medical ICU   (United States)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN S; HYDROXYUREA;

ANEMIA; ANTERIOR CEREBRAL ARTERY; ARTERY BLOOD FLOW; ARTICLE; BLOOD FLOW VELOCITY; BLOOD TRANSFUSION; BRAIN INFARCTION; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR ACCIDENT; CHILD; DONOR; DOPPLER ECHOGRAPHY; FEMALE; FOLLOW UP; GENOIDENTICAL DONOR; HEMATOLOGICAL PARAMETERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; INTERNAL CAROTID ARTERY; LONG TERM CARE; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE CEREBRAL ARTERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; RETICULOCYTE COUNT; RISK FACTOR; SICKLE CELL ANEMIA; STENOSIS; TIME AVERAGED MAXIMUM MEAN VELOCITY; TREATMENT DURATION; ANEMIA, SICKLE CELL; BRAIN CIRCULATION; CLINICAL TRIAL; ECHOGRAPHY; INFANT; PATHOPHYSIOLOGY; STROKE; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY;

ANEMIA, SICKLE CELL; BLOOD FLOW VELOCITY; BLOOD TRANSFUSION; CEREBROVASCULAR CIRCULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; INFANT; MALE; STROKE; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84963628522     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-675231     Document Type: Article

References (44)

1. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-294.
2. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326(9):605-610.
3. Verlhac S, Bernaudin F, Tortrat D, et al. Detection of cerebrovascular disease in patients with sickle cell disease using transcranial Doppler sonography: correlation with MRI, MRA and conventional angiography. Pediatr Radiol. 1995;25(Suppl 1):S14-S19.
4. Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol. 1997;42(5):699-704.
5. Verlhac S, Bernaudin F, Brugières P. Transcranial color Doppler in children with sickle cell disease [in French]. J Radiol. 2003;84(2 Pt 1):131-138.
6. Verlhac S. Transcranial Doppler in children. Pediatr Radiol. 2011;41(Suppl 1):S153-S165.
7. Neish AS, Blews DE, Simms CA, Merritt RK, Spinks AJ. Screening for stroke in sickle cell anemia: comparison of transcranial Doppler imaging and nonimaging US techniques. Radiology. 2002;222(3):709-714.
8. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11.
9. Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood. 2004;104(2):336-339.
10. Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011;117(4):1130-1140, quiz 1436.
11. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103(11):4023-4027.
12. Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica. 2007;92(7):905-912.
13. Files B, Brambilla D, Kutlar A, et al. Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). J Pediatr Hematol Oncol. 2002;24(4):284-290.
14. Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769-2778.
15. Adams RJ, Nichols FT, McKie VC, et al. Transcranial Doppler: influence of hematocrit in children with sickle cell anemia without stroke. J Cardiovasc Technol. 1989;8:97-101.
16. Charache S, Terrin ML, Moore RD, et al; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.
17. de Montalembert M, Belloy M, Bernaudin F, et al; The French Study Group on Sickle Cell Disease. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. J Pediatr Hematol Oncol. 1997;19(4):313-318.
18. Bernaudin F, Lesprit E, Akou'ou MH, et al. Single centre experience of long-term use of hydroxyurea-therapy for pediatric SCD patients: interest of HU for patients with severe anemia [abstract]. New York, NY: National Sickle Cell Disease Program; 2001.
19. Bernaudin F, Verlhac S, Cöíc L, Lesprit E, Brugières P, Reinert P. Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. Pediatr Radiol. 2005;35(3):242-248.
20. Bernaudin F, Souillet G, Vannier JP, et al. Sickle cell disease and BMT: report of the French experience concerning 26 children transplanted for severe SCD. Bone Marrow Transplant. 1997;19(S2):112-115.
21. Bernaudin F, Socie G, Kuentz M, et al; SFGM-TC. Long-term results of related myeloablative stemcell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749-2756.
22. Verlhac S, Balandra S, Cussenot I, et al. Extracranial carotid arteriopathy in stroke-free children with sickle cell anemia: detection by submandibular Doppler sonography. Pediatr Radiol. 2014;44(5):587-596.
23. Bernaudin F, Verlhac S, Arnaud C, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood. 2015;125(10):1653-1661.
24. Helton KJ, Adams RJ, Kesler KL, et al; SWiTCH Investigators. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood. 2014;124(6):891-898.
25. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79(10):2555-2565.
26. Bulas DI, Jones A, Seibert JJ, Driscoll C, O'Donnell R, Adams RJ. Transcranial Doppler (TCD) screening for stroke prevention in sickle cell anemia: pitfalls in technique variation. Pediatr Radiol. 2000;30(11):733-738.
27. Jones AM, Seibert JJ, Nichols FT, et al. Comparison of transcranial color Doppler imaging (TCDI) and transcranial Doppler (TCD) in children with sickle-cell anemia. Pediatr Radiol. 2001;31(7):461-469.
28. McCarville MB, Li C, Xiong X, Wang W. Comparison of transcranial Doppler sonography with and without imaging in the evaluation of children with sickle cell anemia. AJR Am J Roentgenol. 2004;183(4):1117-1122.
29. Adams RJ. TCD in sickle cell disease: an important and useful test. Pediatr Radiol. 2005;35(3):229-234.
30. HAS Syndromes drepanocytaires majeurs de l'enfant et l'adolescent. Protocole national de diagnostic et de soins pour une maladie rare. Available at: http://www.has-sante.fr. Accessed January 15, 2016.
31. Kwiatkowski JL, Granger S, Brambilla DJ, Brown RC, Miller ST, Adams RJ; STOP Trial Investigators. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. Br J Haematol. 2006;134(3):333-339.
32. Imran H, Aygun B, Davis BR, et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the TWiTCH trial [abstract]. Blood. 2014;124(21):87.
33. Kwiatkowski JL, Yim E, Miller S, Adams RJ; STOP 2 Study Investigators. Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease. Pediatr Blood Cancer. 2011;56(5):777-782.
34. Abboud MR, Cure J, Granger S, et al; STOP study. Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. Blood. 2004;103(7):2822-2826.
35. Bernaudin F, Bories D, Dalle JH, et al. Sickle cell anemia and HSCT: relation between ATG, chimerism, GvHD and outcome in myeloablative genoidentical transplants for the SFGM-TC. Blood. 2013;122(21):971.
36. Bernaudin F, Verlhac S, Peffault Delatour R, et al. Cerebral arterial velocities in SCA-children with abnormal doppler are reduced and normalized more frequently after transplantation than after transfusion program (French National Trial "Drepagreffe" AP-HP No: NCT 01340404) [abstract]. Blood. 2014;124(21). Abstract 561.
37. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 2007;110(3):1043-1047.
38. Bernaudin F, Verlhac S, Chevret S, et al. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood. 2008;112(10):4314-4317.
39. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999;94(9):3022-3026.
40. Ware RE, Helms RW; SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119(17):3925-3932.
41. National Institutes of Health. NIH ends transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH) clinical trial due to early results. http://www.nih.gov/news-events/news-releases/nih-endstranscranialdoppler-tcd-transfusions-changinghydroxyureatwitch-clinical-trial-due-early-results. Accessed January 15, 2016.
42. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, openlabel, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661-670.
43. Adams RJ, Brambilla DJ, Granger S, et al; STOP Study. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood. 2004;103(10):3689-3694.
44. Lee MT, Piomelli S, Granger S, et al; STOP Study Investigators. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood. 2006;108(3):847-852.